Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1292P - Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001: A phase I/II trial of selpercatinib

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Anna Minchom

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

A.R. Minchom1, D.S.W. Tan2, E. Massarelli3, V. Subbiah4, V. Boni5, B. Robinson6, L.J. Wirth7, L.M. Hess8, X. Huang9, J.F. Kherani10, E. Olek11, C.E. McCoach12

Author affiliations

  • 1 Drug Development Phase I Unit, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 2 Medicine, NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG
  • 3 Medical Oncology Department, City of Hope Comprehensive Cancer Center, 91010 - Duarte/US
  • 4 Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 5 Oncology Department, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, 28050 - Madrid/ES
  • 6 Cancer Genetics Unit, The University of Sydney, Sydney/AU
  • 7 Center For Head And Neck Cancers, Massachusetts General Hospital, Harvard Medical School, 2114 - Boston/US
  • 8 Global Patient Outcomes And Real World Evidence, Eli Lilly and Company, 46285 - Indianapolis/US
  • 9 Biostatistics, Loxo Oncology at Lilly, San Francisco/US
  • 10 Clinical Research And Development, Loxo Oncology at Lilly, Stamford/US
  • 11 Clinical Research And Development Department, Loxo Oncology at Lilly, South San Francisco/US
  • 12 Medical Oncology, USCF Helen Diller Family Comprehensive Cancer Center, San Francisco/US
More

Resources

Abstract 1292P

Background

Selpercatinib (LOXO-292) is a selective RET inhibitor that has demonstrated robust and durable anti-tumor activity in RET-fusion positive NSCLC. Within the registrational trial, LIBRETTO-001 (NCT03157128), patients received twice daily oral selpercatinib in 28-day cycles. Descriptive PRO data were an exploratory endpoint of the trial; the December 2019 interim analysis are reported.

Methods

Patients with NSCLC completed the validated European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) prior to initiating study treatment and approximately every 8 weeks. All subscales are scored 0-100; higher scores indicate better functioning or more severe symptoms. A clinically meaningful difference (CMD) was pre-defined as ≥10-point change from baseline. Results are reported descriptively by cycle and as mean change from baseline; each patient was categorized as “improved” or “worsened” at each study visit if the CMD was met versus their baseline score.

Results

As of the database lock, 184 patients with NSCLC completed a baseline assessment; adherence was >85% at each scheduled visit. Baseline physical, emotional, cognitive and social subscales were >70 points. The mean baseline global health status was 61.5 (standard deviation, SD=23.6). The highest mean baseline symptom scores were fatigue (37.9, SD=26.0) and insomnia (28.1, SD=30.9). Mean post-baseline subscale scores reached CMD improvements among >30% of patients for physical function and 45% or more of patients for global health status and fatigue (Table of worsened and improved; unchanged not reported). Table: 1292P

QLQ-C30, n (%) Cycle 3 (n=159) Cycle 5(n=134) Cycle 7(n=110) Cycle 9 (n=69) Cycle 11(n=49)
Physical Function Improved 51 (32.1) 47 (35.1) 37 (33.6) 26 (37.7) 21 (42.9)
Worsened 20 (12.6) 16 (11.9) 13 (11.8) 4 (5.8) 5 (10.2)
Global Health Status Improved 71 (45.5)a 71 (54.2)b 58 (53.2)c 36 (53.7)d 27 (55.1)
Worsened 29 (18.6)a 18 (13.7)b 16 (14.7)c 7 (10.4)d 5 (10.2)
Fatigue Improved 71 (44.9) 67 (50.0) 53 (48.2) 33 (47.8) 22 (44.9)
Worsened 39 (24.7) 26 (19.4) 25 (22.7) 18 (26.1) 11 (22.4)
Insomnia Improved 38 (23.9) 39 (29.1) 33 (30.0) 19 (27.5) 20 (40.8)
Worsened 33 (20.8) 20 (14.9) 19 (17.3) 9 (13.0) 6 (12.2)

an=156; bn=131; cn=109; dn=67

Conclusions

The proportion of patients reaching a CMD suggests a subset of patients with NSCLC who may have improvements on some PROs during therapy with selpercatinib. This is a preliminary interim analysis; patients continue to be enrolled to LIBRETTO-001.

Clinical trial identification

NCT03157128.

Editorial acknowledgement

Legal entity responsible for the study

Loxo Oncology.

Funding

Loxo Oncology.

Disclosure

A.R. Minchom: Travel/Accommodation/Expenses: Loxo Oncology; Honoraria (self): Janssen; Honoraria (self): Faron Pharmaceuticals; Honoraria (self): Bayer Pharmaceuticals; Honoraria (self): Novartis Oncology; Honoraria (self): Merck. D.S.W. Tan: Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Research grant/Funding (institution): Celgene; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Eli Lilly and Company; Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy: Merck; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self): Roche; Advisory/Consultancy: Takeda; Research grant/Funding (institution): GlaxoSmithKline; Advisory/Consultancy: Merrimack. V. Subbiah: Advisory/Consultancy, Research grant/Funding (institution): Loxo Oncology; Research grant/Funding (institution): Roche/Genentech; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): GlaxoSmithKline; Research grant/Funding (institution): Nanocarrier; Research grant/Funding (institution): Vegenics; Research grant/Funding (institution): Celgene; Research grant/Funding (institution): Northwest Biotherapeutics; Research grant/Funding (institution): Berghealth; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): Fugifilm; Research grant/Funding (institution): PharmaMar; Research grant/Funding (institution): D3; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Multivir; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Alfa-sigma; Research grant/Funding (institution): Agensys; Research grant/Funding (institution): Boston Biomedical; Research grant/Funding (institution): Idera Pharma; Research grant/Funding (institution): Inhirbrx; Research grant/Funding (institution): Exelixis; Research grant/Funding (institution): Blueprint medicines; Advisory/Consultancy, Research grant/Funding (institution): MedImmune; Research grant/Funding (institution): Altum; Research grant/Funding (institution): Dragonfly therapeutics; Research grant/Funding (institution): Takeda; Advisory/Consultancy, Research grant/Funding (institution): Helsinn. B. Robinson: Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy: Eli Lilly and Company; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai. L.J. Wirth: Research grant/Funding (institution): Loxo Oncology; Honoraria (self): Bayer; Honoraria (self): Blueprint Medicine; Honoraria (self): Cue Biopharma; Honoraria (self): Eisai; Honoraria (self): Exelixis; Honoraria (self): Genentech; Honoraria (self): Eli Lilly and Company; Honoraria (self): Merck; Honoraria (self): Rakuten Medical. L.M. Hess: Full/Part-time employment: Eli Lilly and Company. X. Huang, J.F. Kherani, E. Olek: Full/Part-time employment: Loxo Oncology. C. McCoach: Honoraria (self), Research grant/Funding (institution): Novatis; Honoraria (self): Guardant Health; Advisory/Consultancy: Genentech; Research grant/Funding (institution): Revolution Medicines. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings